This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2025 Apr 3;15(1):56.

doi: 10.1038/s41408-025-01270-4.

Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days

Naseema Gangat¹, Ayalew Tefferi²

Affiliations

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, MN, USA. gangat.naseema@mayo.edu.
² Division of Hematology, Mayo Clinic, Rochester, MN, USA.

PMID: 40180902
PMCID: PMC11968881
DOI: 10.1038/s41408-025-01270-4

Editorial

Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days

Naseema Gangat et al. Blood Cancer J. 2025.

. 2025 Apr 3;15(1):56.

doi: 10.1038/s41408-025-01270-4.

Authors

Naseema Gangat¹, Ayalew Tefferi²

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, MN, USA. gangat.naseema@mayo.edu.
² Division of Hematology, Mayo Clinic, Rochester, MN, USA.

PMID: 40180902
PMCID: PMC11968881
DOI: 10.1038/s41408-025-01270-4

Abstract

Venotoclax schedule in acute myeloid leukemia.

© 2025. The Author(s).

PubMed Disclaimer

Conflict of interest statement

Competing interests: NG has served on the Advisory Board for Agio and DISC Medicine.

Figures

None — Venotoclax schedule in acute myeloid leukemia

See this image and copyright information in PMC

Similar articles

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. DiNardo CD, et al. Lancet Haematol. 2020 Oct;7(10):e724-e736. doi: 10.1016/S2352-3026(20)30210-6. Epub 2020 Sep 5. Lancet Haematol. 2020. PMID: 32896301 Free PMC article. Clinical Trial.
CPX-351 (Vyxeos) in Acute Myeloid Leukemia: Time to Move on?
Gangat N, Tefferi A. Gangat N, et al. Am J Hematol. 2025 Aug;100(8):1271-1276. doi: 10.1002/ajh.27730. Epub 2025 May 29. Am J Hematol. 2025. PMID: 40439474
Venetoclax (Venclexta) for chronic lymphocytic leukemia.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2016 Aug 1;58(1500):101-2. Med Lett Drugs Ther. 2016. PMID: 27466751 No abstract available.
New drugs approved for acute myeloid leukaemia in 2018.
Kucukyurt S, Eskazan AE. Kucukyurt S, et al. Br J Clin Pharmacol. 2019 Dec;85(12):2689-2693. doi: 10.1111/bcp.14105. Epub 2019 Dec 13. Br J Clin Pharmacol. 2019. PMID: 31469910 Free PMC article. Review.
Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia.
Goulart H, Kantarjian H, Pemmaraju N, Daver N, DiNardo CD, Rausch CR, Ravandi F, Kadia TM. Goulart H, et al. Blood Cancer Discov. 2025 Jan 8;6(1):23-37. doi: 10.1158/2643-3230.BCD-24-0171. Blood Cancer Discov. 2025. PMID: 39565177 Free PMC article. Review.

See all similar articles

Cited by

Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine-venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net.
Kanaya M, Onozawa M, Matsukawa T, Miyashita N, Fujii F, Yoshida S, Nagai J, Aiba M, Hidaka D, Hashiguchi J, Senjo H, Igarashi T, Chiba M, Yamamoto S, Shimizu T, Ishio T, Yokoyama S, Ebata K, Iyama S, Oyake T, Kondo T, Teshima T. Kanaya M, et al. Blood Cancer J. 2025 Jul 3;15(1):118. doi: 10.1038/s41408-025-01324-7. Blood Cancer J. 2025. PMID: 40610408 Free PMC article. No abstract available.
Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms.
Gangat N, Dinardo CD. Gangat N, et al. Blood Cancer J. 2025 Aug 16;15(1):139. doi: 10.1038/s41408-025-01346-1. Blood Cancer J. 2025. PMID: 40818987 Free PMC article. Review.
Comprehensive view on chemotherapy-free management of acute myeloid leukemia by using venetoclax in combination with targeted and/or immune therapies.
Kegyes D, Tat A, Vizitiu AS, Vazar-Tripon D, Ilie R, Tigu AB, Cenariu D, Bancos A, Iluta S, Jitaru C, Nistor M, Tomai R, Gulei D, Zdrenghea M, Einsele H, Ghiaur G, Croce CM, Tomuleasa C. Kegyes D, et al. Cell Death Discov. 2025 Aug 13;11(1):379. doi: 10.1038/s41420-025-02678-4. Cell Death Discov. 2025. PMID: 40804253 Free PMC article. Review.

References

1. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–29. - PubMed
1. Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol. 2025. 10.1002/ajh.27625. Online ahead of print. - PMC - PubMed
1. Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, et al. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia. 1999;13:1881–92. - PubMed
1. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4:362–75. - PMC - PubMed
1. Bogenberger JM, Delman D, Hansen N, Valdez R, Fauble V, Mesa RA, et al. Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma. 2015;56:226–9. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- PubMed Central
Medical
- MedlinePlus Health Information